Literature DB >> 32882427

Interaction Between Alcohol Consumption and PNPLA3 Variant in the Prevalence of Hepatic Steatosis in the US Population.

Mariana Lazo1, Usama Bilal2, Mack C Mitchell3, James Potter4, Ruben Hernaez5, Jeanne M Clark6.   

Abstract

BACKGROUND & AIMS: To our knowledge, the interaction between alcohol consumption and PNPLA3 genotype on hepatic steatosis has not been explored in a representative sample. To examine the interaction between alcohol consumption and PNPLA3 genotype on hepatic steatosis in the US adult population.
METHODS: Cross-sectional study of 4,674 adult participants of the Third National Health and Nutrition Examination Survey, Phase 2 (1991-1994) with data on PNPLA3 genotype, self-reported alcohol consumption, ultrasound-defined hepatic steatosis and socio-demographic characteristics.
RESULTS: In 1991-1994 in the U.S. population, the weighted allele frequency of the G (risk) allele of the rs738409 at PNPLA3 was 25.4%. We confirmed both a J shaped association between alcohol consumption and hepatic steatosis among those with the CC genotype of PNPLA3, and a higher prevalence of hepatic steatosis among those with PNPLA3 gene G variant. We found evidence of an interaction of PNPLA3 G allele presence on the association between moderate alcohol consumption and hepatic steatosis on both the multiplicative (relative prevalence ratio [RPR]=1.95, 95% confidence interval [CI] 1.04-3.65) and additive scales (relative excess risk due to interaction=0.49, 95% CI 0.13-0.85). Compared to never drinkers, moderate alcohol drinking was associated with a 48% decreased risk of hepatic steatosis only among those without PNPLA3 G allele (PR=0.52, 95% CI 0.26-1.05), with no association among those with at least one copy of the PNPLA3 G allele (PR=1.02, 95% CI 0.68-1.54).
CONCLUSIONS: Our results suggest that a highly common and strong genetic susceptibility to liver disease is modifiable by the level of alcohol consumption. Keeping alcohol consumption low may offset genetic predisposition to liver disease.
Copyright © 2021 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adults; Alcohol Drinking; Fatty Liver; Genetic Predisposition to Disease; Nutrition Surveys

Mesh:

Substances:

Year:  2020        PMID: 32882427      PMCID: PMC7914282          DOI: 10.1016/j.cgh.2020.08.054

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  39 in total

1.  Implementation of the Lancet Standing Commission on Liver Disease in the UK.

Authors:  Roger Williams; Kathryn Ashton; Richard Aspinall; Mark A Bellis; Joanne Bosanquet; Matthew E Cramp; Natalie Day; Anil Dhawan; John Dillon; Jessica Dyson; James Ferguson; Graham Foster; Sir Ian Gilmore; Michael Glynn; J Ashley Guthrie; Mark Hudson; Deirdre Kelly; Andrew Langford; Philip Newsome; John O'Grady; Rachel Pryke; Stephen Ryder; Marianne Samyn; Nick Sheron; Julia Verne
Journal:  Lancet       Date:  2015-11-20       Impact factor: 79.321

Review 2.  Alcoholic liver disease.

Authors:  Robert S O'Shea; Srinivasan Dasarathy; Arthur J McCullough
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

3.  A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis.

Authors:  Stephan Buch; Felix Stickel; Eric Trépo; Michael Way; Alexander Herrmann; Hans Dieter Nischalke; Mario Brosch; Jonas Rosendahl; Thomas Berg; Monika Ridinger; Marcella Rietschel; Andrew McQuillin; Josef Frank; Falk Kiefer; Stefan Schreiber; Wolfgang Lieb; Michael Soyka; Nasser Semmo; Elmar Aigner; Christian Datz; Renate Schmelz; Stefan Brückner; Sebastian Zeissig; Anna-Magdalena Stephan; Norbert Wodarz; Jacques Devière; Nicolas Clumeck; Christoph Sarrazin; Frank Lammert; Thierry Gustot; Pierre Deltenre; Henry Völzke; Markus M Lerch; Julia Mayerle; Florian Eyer; Clemens Schafmayer; Sven Cichon; Markus M Nöthen; Michael Nothnagel; David Ellinghaus; Klaus Huse; Andre Franke; Steffen Zopf; Claus Hellerbrand; Christophe Moreno; Denis Franchimont; Marsha Y Morgan; Jochen Hampe
Journal:  Nat Genet       Date:  2015-10-19       Impact factor: 38.330

4.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  J Hepatol       Date:  2016-04-07       Impact factor: 25.083

5.  Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population.

Authors:  Fredrik Åberg; Jaana Helenius-Hietala; Pauli Puukka; Martti Färkkilä; Antti Jula
Journal:  Hepatology       Date:  2018-04-16       Impact factor: 17.425

Review 6.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Authors:  Andrew M Moon; Amit G Singal; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-08       Impact factor: 11.382

7.  Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta-analysis.

Authors:  Nicole E Rich; Stefany Oji; Arjmand R Mufti; Jeffrey D Browning; Neehar D Parikh; Mobolaji Odewole; Helen Mayo; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2017-09-29       Impact factor: 11.382

8.  Pnpla3/Adiponutrin deficiency in mice does not contribute to fatty liver disease or metabolic syndrome.

Authors:  Mahesh K Basantani; Mitch T Sitnick; Lingzhi Cai; Daniel S Brenner; Noah P Gardner; John Zhong Li; Gabriele Schoiswohl; Kui Yang; Manju Kumari; Richard W Gross; Rudolf Zechner; Erin E Kershaw
Journal:  J Lipid Res       Date:  2010-11-09       Impact factor: 5.922

9.  Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.

Authors:  Daniel Lindén; Andrea Ahnmark; Piero Pingitore; Ester Ciociola; Ingela Ahlstedt; Anne-Christine Andréasson; Kavitha Sasidharan; Katja Madeyski-Bengtson; Magdalena Zurek; Rosellina M Mancina; Anna Lindblom; Mikael Bjursell; Gerhard Böttcher; Marcus Ståhlman; Mohammad Bohlooly-Y; William G Haynes; Björn Carlsson; Mark Graham; Richard Lee; Sue Murray; Luca Valenti; Sanjay Bhanot; Peter Åkerblad; Stefano Romeo
Journal:  Mol Metab       Date:  2019-02-05       Impact factor: 7.422

10.  Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis.

Authors:  Soumik BasuRay; Yang Wang; Eriks Smagris; Jonathan C Cohen; Helen H Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.